PTPA and laryngotracheoesophageal cleft: The growing awareness of the impact of PP2A endogenous inhibitors in COPD and LC suggests that targeting these inhibiting agents may have beneficial therapeutic effects through the reactivation of anti-inflammatory and tumour suppressive functions of PP2A.